IONS
IONIS PHARMACEUTICALS INC
Nasdaq: IONS · Carlsbad, CA · Healthcare
Market Cap—
Cash$372.3Mmost recent
Runway7 mo$150.8M Q burn
P/E (TTM)—EPS $-2.38
52-Wk Range—
Avg Volume—3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$74.78+82.1%
Pipeline

Drug candidates sponsored by IONIS PHARMACEUTICALS · ClinicalTrials.gov

64 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 3ISIS 3521
Lung Cancer
Completed
2002-09-09past
1
Phase 3Alicaforsen
Crohn's Disease+1 more
Completed
2004-10-11past
3
Phase 3Volanesorsen
Familial Chylomicronemia Syndrome
Completed
2016-12-19past
1
Phase 2Inotersen
FAP+6 more
Completed
2023-04-11past
4
Phase 3zilganersen
Alexander Disease
Active, not recruiting
2025-08-22past
2
Phase 3Donidalorsen
Hereditary Angioedema+1 more
Recruiting
2026-12
6
Phase 3Olezarsen
Familial Chylomicronemia Syndrome+6 more
Active, not recruiting
2027-03
10
Phase 3ION582
Angelman Syndrome
Recruiting
2027-08
1
Phase 3Eplontersen
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)+2 more
Active, not recruiting
2029-08
3
Phase 2ISIS 104838
Rheumatoid Arthritis
Completed
2003-02-01past
1
Phase 1ISIS 14803, peginterferon alfa, ribavirin
Hepatitis C, Chronic
Completed
2004-01past
1
Phase 2ISIS 14803
Hepatitis C, Chronic
Completed
2004-05-01past
1
Phase 2ISIS 113715
Type 2 Diabetes Mellitus
Completed
2007-03-01past
4
Phase 1ISIS EIF4E Rx
Non-small Cell Lung Cancer+1 more
Completed
2013-05past
2
Phase 2ISIS CRP Rx or Placebo
Rheumatoid Arthritis
Completed
2013-05past
1
Phase 2ISIS-APOCIIIRX
Type 2 Diabetes
Terminated
2014-01past
1
Phase 2ISIS apoC-III Rx
Hypertriglyceridemia
Completed
2014-01past
1
Phase 2ISIS CRP Rx
Paroxysmal Atrial Fibrillation
Completed
2014-04past
1
Phase 2ISIS-GCGRRx - Dose Level 1
Type 2 Diabetes Mellitus
Completed
2014-05past
1
Phase 2ISIS-FXIRx Dose #2
Venous Thromboembolism
Completed
2014-05past
1
Phase 2ISIS-PTP1BRx
Type 2 Diabetes Mellitus+1 more
Completed
2014-10past
1
Phase 2ISIS-GCCRRx
Type 2 Diabetes Mellitus
Completed
2015-01past
1
Phase 2ISIS-APO(a)Rx
Elevated Lipoprotein(a)
Completed
2015-11past
1
Phase 1IONIS-STAT3Rx
Advanced Cancers+2 more
Completed
2016-03-23past
1
Phase 2ISIS-FGFR4RX
Obesity
Completed
2016-07past
1
Phase 1IONIS-DMPKRx
Myotonic Dystrophy Type 1
Completed
2016-07past
1
Phase 2ISIS-GCGRRx
Type 2 Diabetes
Completed
2016-12-15past
1
Phase 2ISIS-GCGRRx- Dose Level 1
Type 2 Diabetes
Completed
2016-12-15past
1
Phase 1ISIS 443139 10 mg
Huntington's Disease
Completed
2017-11-08past
1
Phase 2IONIS DGAT2Rx
Hepatic Steatosis
Completed
2018-11-28past
1
Phase 2ISIS 416858
End-stage Renal Disease (ESRD)
Completed
2019-07-10past
2
Phase 1ION-682884
Healthy Volunteers+1 more
Completed
2020-02-20past
1
Phase 2IONIS-GHR-LRx
Acromegaly
Completed
2021-02-18past
1
Phase 2ION-827359
Chronic Bronchitis+1 more
Terminated
2021-04-27past
1
Phase 2Placebo
Mild Hypertension+3 more
Completed
2022-06-29past
5
Phase 2GHR-LRX
Acromegaly
Completed
2022-07-15past
1
Phase 2IONIS-AGT-LRx
Chronic Heart Failure With Reduced Ejection Fraction
Completed
2022-10-19past
1
Phase 2ION904
Hypertension+1 more
Completed
2023-01-31past
2
Phase 2sapablursen
Beta Thalassemia Intermedia
Terminated
2023-03-28past
1
Phase 2ION224
Steatohepatitis, Nonalcoholic
Completed
2024-01-10past
1
Phase 2IONIS-FB-Lrx
Geographic Atrophy+3 more
Completed
2024-04-18past
3
Phase 1ION717
Prion Disease
Recruiting
2027-02
1
Phase 1ION440
Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
Recruiting
2027-09
1
Phase 1ION337
Dravet Syndrome
Recruiting
2030-12
1
Phase 2Fomivirsen sodium
Cytomegalovirus Retinitis+1 more
Completed—3
Phase 1ISIS 325568
Type 2 Diabetes Mellitus
Completed
2008-04past
1
Phase 1ISIS 353512
Inflammatory Diseases
Completed
2010-02past
1
Phase 1ISIS 333611
Familial Amyotrophic Lateral Sclerosis
Completed
2011-12past
1
Phase 1IONIS-APO(a)-LRx
Elevated Lipoprotein(a)
Completed
2016-02past
1
Phase 1IONIS ANGPTL3-LRx
Hypertriglyceridemia+1 more
Completed
2017-04-12past
1
Phase 1Ionis AGT-LRx
Healthy Volunteers
Completed
2018-03-29past
1
Phase 1IONIS TMPRSS6-Lrx
Thalassemia
Completed
2018-09-25past
1
Phase 1IONIS-ENaCRx
Healthy Subjects+1 more
Completed
2020-10-13past
1
Phase 1IONIS MAPTRx
Mild Alzheimer's Disease
Completed
2022-05-12past
1
Phase 1ION547
Healthy Volunteers
Completed
2022-09-14past
1
Phase 1ION537
Advanced Solid Tumors
Completed
2022-10-19past
1
Phase 1BIIB094
Parkinson's Disease
Completed
2024-08-12past
1
Phase 1ION251
Relapsed Multiple Myeloma+1 more
Completed
2024-09-30past
1
Phase 1ION269
Alzheimer Disease+1 more
Terminated
2025-12-03past
1
Phase 1ION464
Multiple System Atrophy
Recruiting
2027-09
1
N/AUnnamed
Lafora Disease
Completed
2022-04-01past
1
N/AUnnamed
Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
Terminated
2025-10-07past
1
N/AUnnamed
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Active, not recruiting
2026-03past
1
N/AUnnamed
Pelizaeus-Merzbacher Disease
Recruiting
2029-03
1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for IONS. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.